In the last decade, the organization of pharmaceutical research on neglected tropical diseases has undergone transformative change. In a context of perceived “market failure,” the development of new medicines is increasingly handled by public-private partnerships. This shift toward hybrid organizational models depends on a particular form of exchange: the sharing of proprietary assets in general and of intellectual property rights in particular. 

Publication details 

Javier Lezaun, Catherine M. Montgomery
Science, Technology & Human Values
0162243914542349, July 11, 2014